Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on cholestasis, intrahepatic, of pregnancy, type 3 is limited due to its rarity and the recent identification of its genetic basis. Conditions like ICP3 affect a small number of individuals, which hampers extensive clinical studies and comprehensive data collection. As research continues to evolve, more information may become available to better characterize this condition.
The primary clinical feature of cholestasis, intrahepatic, of pregnancy, type 3 is jaundice, which can occur in 5-29% of cases. This symptom arises due to the impaired bile flow during pregnancy, leading to an accumulation of bile acids in the liver and bloodstream. While jaundice is the most notable symptom, other potential manifestations may include itching and abdominal discomfort, but these are less frequently reported.
To navigate your care for cholestasis, intrahepatic, of pregnancy, type 3, consider seeking a maternal-fetal medicine specialist or a hepatologist with expertise in liver conditions during pregnancy. These specialists can provide tailored management strategies based on your specific symptoms and needs. Additionally, genetic counseling may be beneficial, especially if you are considering family planning, as it can provide insights into inheritance patterns. For more information and resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Currently, there are no orphan drugs designated for cholestasis, intrahepatic, of pregnancy, type 3. However, there is one active clinical trial that may provide insights into the condition and potential management strategies. You can find more information about ongoing research by visiting ClinicalTrials.gov and searching for 'cholestasis, intrahepatic, of pregnancy, 3'. This trial may offer opportunities for participation and contribute to understanding the condition better.
Actionable guidance for navigating care for cholestasis, intrahepatic, of pregnancy, 3
To navigate your care for cholestasis, intrahepatic, of pregnancy, type 3, consider seeking a maternal-fetal medicine specialist or a hepatologist with expertise in liver conditions during pregnancy. These specialists can provide tailored management strategies based on your specific symptoms and needs. Additionally, genetic counseling may be beneficial, especially if you are considering family planning, as it can provide insights into inheritance patterns. For more information and resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on cholestasis, intrahepatic, of pregnancy, type 3 is limited due to its rarity and the recent identification of its genetic basis. Conditions like ICP3 affect a small number of individuals, which hampers extensive clinical studies and comprehensive data collection. As research continues to evolve, more information may become available to better characterize this condition.
The primary clinical feature of cholestasis, intrahepatic, of pregnancy, type 3 is jaundice, which can occur in 5-29% of cases. This symptom arises due to the impaired bile flow during pregnancy, leading to an accumulation of bile acids in the liver and bloodstream. While jaundice is the most notable symptom, other potential manifestations may include itching and abdominal discomfort, but these are less frequently reported.
To navigate your care for cholestasis, intrahepatic, of pregnancy, type 3, consider seeking a maternal-fetal medicine specialist or a hepatologist with expertise in liver conditions during pregnancy. These specialists can provide tailored management strategies based on your specific symptoms and needs. Additionally, genetic counseling may be beneficial, especially if you are considering family planning, as it can provide insights into inheritance patterns. For more information and resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Currently, there are no orphan drugs designated for cholestasis, intrahepatic, of pregnancy, type 3. However, there is one active clinical trial that may provide insights into the condition and potential management strategies. You can find more information about ongoing research by visiting ClinicalTrials.gov and searching for 'cholestasis, intrahepatic, of pregnancy, 3'. This trial may offer opportunities for participation and contribute to understanding the condition better.
Actionable guidance for navigating care for cholestasis, intrahepatic, of pregnancy, 3
To navigate your care for cholestasis, intrahepatic, of pregnancy, type 3, consider seeking a maternal-fetal medicine specialist or a hepatologist with expertise in liver conditions during pregnancy. These specialists can provide tailored management strategies based on your specific symptoms and needs. Additionally, genetic counseling may be beneficial, especially if you are considering family planning, as it can provide insights into inheritance patterns. For more information and resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on cholestasis, intrahepatic, of pregnancy, type 3 is limited due to its rarity and the recent identification of its genetic basis. Conditions like ICP3 affect a small number of individuals, which hampers extensive clinical studies and comprehensive data collection. As research continues to evolve, more information may become available to better characterize this condition.
The primary clinical feature of cholestasis, intrahepatic, of pregnancy, type 3 is jaundice, which can occur in 5-29% of cases. This symptom arises due to the impaired bile flow during pregnancy, leading to an accumulation of bile acids in the liver and bloodstream. While jaundice is the most notable symptom, other potential manifestations may include itching and abdominal discomfort, but these are less frequently reported.
To navigate your care for cholestasis, intrahepatic, of pregnancy, type 3, consider seeking a maternal-fetal medicine specialist or a hepatologist with expertise in liver conditions during pregnancy. These specialists can provide tailored management strategies based on your specific symptoms and needs. Additionally, genetic counseling may be beneficial, especially if you are considering family planning, as it can provide insights into inheritance patterns. For more information and resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Currently, there are no orphan drugs designated for cholestasis, intrahepatic, of pregnancy, type 3. However, there is one active clinical trial that may provide insights into the condition and potential management strategies. You can find more information about ongoing research by visiting ClinicalTrials.gov and searching for 'cholestasis, intrahepatic, of pregnancy, 3'. This trial may offer opportunities for participation and contribute to understanding the condition better.
Actionable guidance for navigating care for cholestasis, intrahepatic, of pregnancy, 3
To navigate your care for cholestasis, intrahepatic, of pregnancy, type 3, consider seeking a maternal-fetal medicine specialist or a hepatologist with expertise in liver conditions during pregnancy. These specialists can provide tailored management strategies based on your specific symptoms and needs. Additionally, genetic counseling may be beneficial, especially if you are considering family planning, as it can provide insights into inheritance patterns. For more information and resources, visit the Genetic and Rare Diseases Information Center at rarediseases.info.nih.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 8, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.